We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Funding Awarded to Develop Diagnostic Point-of-Care Device for Sickle Cell Disease

By LabMedica International staff writers
Posted on 21 Sep 2014
Print article
Rockland Immunochemicals, Inc. (Limerick, PA, USA) has announced the award of a USD 224,473 Small Business Innovation Research (SBIR) grant from the NIH National Heart Lung and Blood Institute (NHLBI) to develop an antibody-based point-of-care device for the diagnosis of Sickle Cell Disease (SCD), a mutation carried in approximately 7% of the world’s population. Rockland secured the award by demonstrating the technology and processes it deploys to develop and to produce leading edge life science tools for basic and clinical research focused on functional genomics and drug discovery markets.

Sickle cell anemia (SCA) is the most common form of SCD, which is the 5th most common genetic disorder in the world. Due to the inability of the deformed red blood cells to carry adequate oxygen in affected individuals, SCD is extremely painful. In addition to early detection helping to reduce the risk of life-threatening infections and increase the odds for survival, diagnosis also enables treatment with pain medication that can ease most symptoms, including abdominal, chest and bone pain, fatigue, shortness of breath, accelerated heart rate, delayed puberty, stunted growth, fever, and leg ulcers.

Currently, there are no simple and cost effective screening tests available that can differentiate patients with the sickle cell trait (HbAS) from sickle cell disease conditions (HbSS, HbSC, and HbS β-thalassemias). “Rockland’s antibody technology platform will help to overcome these barriers tremendously. We will create novel hemoglobin isoform-specific antibodies and configure a lateral flow point-of-care assay,” said Dr. Carl Ascoli, Rockland’s chief science officer, “As a result of this project, the antibody-based lateral flow point-of-care device will allow rapid and inexpensive diagnosis of Sickle Cell Disease in infants and young children in industrialized and low-income and low-resource settings.”

Related Links:

Rockland Immunochemicals 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.